Amylyx Pharmaceuticals, Inc. (AMLX) › Capital ExpendituresAmylyx Pharmaceuticals, Inc. (AMLX) — Capital ExpendituresAnnual figures by period end, from SEC filings.2021-12-31: $353.0K2022-12-31: $2.53M2023-12-31: $1.24M2024-12-31: $157.0K2025-12-31: $138.0K$138.0K2021-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$138.0K-12.1%2026-03-03From 2025-01-012024-12-31$157.0K-87.3%2026-03-03From 2024-01-012023-12-31$1.24M-50.9%2025-03-04From 2023-01-012022-12-31$2.53M+615.6%2024-02-22From 2022-01-012021-12-31$353.0K—2024-02-22From 2021-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)